
Health Canada

Fees Report

Fiscal Year 2024-25



Health Canada Santé Canada

Canada

© His Majesty the King in Right of Canada, as represented by the Minister of Health, 2025

Catalogue No. H1-9/35E-PDF

ISSN 2562-3346

This document is available on the Government of Canada website at www.canada.ca

This document is available in alternative formats upon request.

Table of contents

Minister’s message	4
About this report	5
Remissions	6
Overall totals, by fee setting mechanism	7
Totals, by fee grouping, for fees set by act, regulation or fees notice	7
Details on each fee set by act, regulation or fees notice	11
Fees for Examination of a Submission — Drugs for Human Use	12
Certificate of Supplementary Protection Application Fees	24
Master File Fees	25
Fees for Right to Sell Drugs – Human Use	27
Drug Establishment Licensing Fees – Human Use	29
Certificate of Pharmaceutical Product Fee	31
Fees for Examination of a Submission — Drugs for Veterinary Use Only	32
Fees for Right to Sell Drugs – Veterinary Use	55
Drug Establishment Licensing Fees – Veterinary Use	56
Drug Establishment Licensing Fees - Dealer's Licences	58
Fees for Examination of an Application for a Medical Device Licence	60
Fees for Right to Sell a Licensed Class II, III or IV Medical Device	70
Medical Device Establishment Licensing Fees	71
Fees to be Paid for the Examination of an Application in Respect of a Pest Control Product	73
Annual Charge (for a registered Pest Control Product)	121
Fees Charged for Filing a Claim for Exemption under the <i>Hazardous Materials Information Review Act</i>	123
Cannabis Fees	125
National Dosimetry Products and Services Fees	130

Minister's message

On behalf of Health Canada, I am pleased to present the Department's fees report for the 2024-25 fiscal year.

As part of its mandate to help keep people in Canada safe and healthy, Health Canada assesses the safety, efficacy and quality of health products. To minimize costs to Canadian taxpayers, the Department charges fees to the submitting company. Fees are charged for drugs and medical devices, pesticides, hazardous materials, radiation protection and cannabis.

This report covers fee amounts, service standards, performance results, revenues and remissions. Other notable work from this past fiscal year includes:



- Publishing the [*Tobacco Charges Regulations*](#) in Canada Gazette, Part II. The new regulations require companies that manufacture or import tobacco products to pay an annual charge to recover the Government of Canada's costs related to certain tobacco-related activities as outlined in the *Tobacco and Vaping Products Act*. The first annual charges are due by November 30, 2026.
- Publishing proposed amendments to the [*Regulations Amending the Pest Control Products Fees and Charges Regulations \(Annual Charge\)*](#) in Canada Gazette, Part I on December 21, 2024.
- Adding new fees related to [*biocides*](#), which came into effect on May 31, 2025 under the [*Order Amending Fees in Respect of Drugs and Medical Devices Order \(Biocides\)*](#).

Health Canada will continue to work with industry partners to ensure its fee structures are current, relevant and are determined in an open and transparent manner. By collaborating and making evidence-based decisions, we will continue to help ensure that people in Canada have access to safe and effective health products.

The Honourable Marjorie Michel, P.C. M.P.
Minister of Health

About this report

This report, which is tabled under section 20 of the *Service Fees Act*, the *Low-Materiality Fees Regulations*, and subsection 4.2.9 of the Treasury Board *Directive on Charging and Special Financial Authorities*, contains information about the fees Health Canada had the authority to charge in fiscal year 2024-25.

The report covers fees that are subject to the *Service Fees Act* and exempted from the *Service Fees Act*.

For reporting purposes, fees are categorized by fee-setting mechanism. There are three mechanisms:

1. Act, regulation or fees notice
The authority to set these fees is delegated to a department, minister or Governor in Council pursuant to an act of Parliament.
2. Contract
Ministers have the authority to enter into contracts, which are usually negotiated between the minister and an individual or organization, and which cover fees and other terms and conditions. In some cases, that authority may also be provided by an act of Parliament.
3. Market rate or auction
The authority to set these fees comes from an act of Parliament or a regulation, and the minister, department or Governor in Council has no control in determining the fee amount.

For fees set by act, regulation or fees notice, the report provides totals for fee groupings, as well as detailed information for each fee. Health Canada did not have fees set by contract, market rate or auction.

Fees charged by Health Canada under the *Access to Information Act* are not subject to the *Service Fees Act*, and are not included in this report. Information on Health Canada's access to information fees can be found in our [annual report](#) to Parliament on the administration of the *Access to Information Act*.

Remissions

In 2024-25, Health Canada was subject to the requirements to issue remissions under section 7 of the *Service Fees Act* and subsection 4.2.4 of the Treasury Board *Directive on Charging and Special Financial Authorities* to remit a fee, in whole or in part, to a fee payer when a service standard was not met. Health Canada's remission policy and procedures, pursuant to the Service Fees Act, are on the following web page: [Remissions for missed service standards](#)

In 2024-25, Health Canada also issued remissions under its enabling legislation. These remissions may have been for reasons other than not meeting a service standard.

The authority to remit is delegated in the *Food and Drugs Act*, 30.63(1) and is detailed in the [Fees in Respect of Drugs and Medical Devices Order](#).

The other sections of this report provide detailed amounts on Health Canada's remissions for 2024-25.

Overall totals, by fee setting mechanism

The following table presents the total revenue, cost and remissions for all fees that Health Canada had the authority to charge in 2024-25, by fee-setting mechanism.

Overall totals for 2024-25, by fee-setting mechanism

Fee-setting mechanism	Revenue (\$)	Cost (\$)	Remissions (\$)
Fees set by act, regulation or fees notice	317,406,120	672,793,375	1,871,415

Totals, by fee grouping, for fees set by act, regulation or fees notice

A fee grouping is a set of fees relating to a single business line, directorate or program that a department had the authority to set for those activities.

This section presents, for each fee grouping, the total revenue, cost and remissions for all fees that Health Canada had the authority to set in 2024-25 that are set by any of the following:

- act
- regulation
- fees notice

The revenue collections reported below may include: fees from previous years due to the timing of payments and lower fees due to mitigation measures (as per the relevant regulations).

Fees for Examination of a Submission - Drugs for Human Use: totals for 2024-25

Revenue (\$)	Cost (\$)	Remissions (\$)
98,261,696	195,549,161	1,744,484

Certificate of Supplementary Protection Application Fees: totals for 2024-25

Revenue (\$)	Cost (\$)	Remissions (\$)
103,560	157,599	0

Master File Fees: totals for 2024-25

Revenue (\$)	Cost (\$)	Remissions (\$)
988,040	1,415,414	0

Fees for Right to Sell Drugs - Human: totals for 2024-25

Revenue (\$)	Cost (\$)	Remissions (\$)
55,397,982	86,493,302	0

Drug Establishment Licensing Fees - Human: totals for 2024-25

Revenue (\$)	Cost (\$)	Remissions (\$)
32,487,974	41,679,022	0

Certificate of Pharmaceutical Product Fee: totals for 2024-25

Revenue (\$)	Cost (\$)	Remissions (\$)
242,509	725,311	0

Fees for Examination of a Submission - Drugs for Veterinary Use Only: totals for 2024-25

Revenue (\$)	Cost (\$)	Remissions (\$)
1,529,523	13,659,963	0

Fees for Right to Sell Drugs - Vet: totals for 2024-25

Revenue (\$)	Cost (\$)	Remissions (\$)
468,394	1,841,542	0

Drug Establishment Licensing Fees - Vet: totals for 2024-25

Revenue (\$)	Cost (\$)	Remissions (\$)
1,641,965	2,799,674	0

Drug Establishment Licensing Fees - Dealer's Licences: totals for 2024-25

Revenue (\$)	Cost (\$)	Remissions (\$)
486,778	4,641,479	11,370

Fees for Examination of Medical Device Licence Applications: totals for 2024-25

Revenue (\$)	Cost (\$)	Remissions (\$)
12,638,651	31,121,589	2,591

Fees for Right to Sell Licenced Class II, III, or IV Medical Devices: totals for 2024-25

Revenue (\$)	Cost (\$)	Remissions (\$)
13,946,715	35,032,207	0

Medical Devices Establishment Licensing Fees: totals for 2024-25

Revenue (\$)	Cost (\$)	Remissions (\$)
13,397,431	16,062,172	0

Fees to be Paid for the Examination of an Application in Respect of a Pest Control Product: totals for 2024-25

Revenue (\$)	Cost (\$)	Remissions (\$)
5,280,347	60,760,497	111,913

Annual Charge (for a registered Pest Control Product): totals for 2024-25

Revenue (\$)	Cost (\$)	Remissions (\$)
10,284,768	38,684,631	0

Fees Charged for Filing a Claim for Exemption under the *Hazardous Materials Information Review Act*: totals for 2024-25

Revenue (\$)	Cost (\$)	Remissions (\$)
428,092	3,000,316	1,057

Cannabis Fees: totals for 2024-25

Revenue (\$)	Cost (\$)	Remissions (\$)
61,582,371	127,674,704	0

National Dosimetry Products and Services Fees: totals for 2024-25

Revenue (\$)	Cost (\$)	Remissions (\$)
8,239,324	11,494,792	0

Details on each fee set by act, regulation or fees notice

This section provides detailed information on each fee that Health Canada had the authority to charge in 2024-25 and that was set by any of the following:

- act
- regulation
- fees notice

The total of the revenue collections by fee grouping below may not equal the revenues reported in the “Totals, by fee grouping, for fees set by act, regulation or fees notice” section due to small discrepancies in the reports used.

Fees for Examination of a Submission – Drugs for Human Use

Before a drug is authorized for sale in Canada, Health Canada reviews it to assess its safety, efficacy and quality. Drug products include prescription and non-prescription pharmaceuticals, biologics, disinfectants and sanitizers with disinfectant claims.

Fee

New Active Substance

Fee-setting authority

- *Food and Drugs Act (FDA)*, 30.61(1)
- *Fees in Respect of Drugs and Medical Devices Order* (SOR/2019-124)

Year fee-setting authority was introduced

2017

Last year fee-setting authority was amended

2025

Service standard

300 calendar days to complete Review 1

Performance result

90.7% (39/43 completed within service standard)

Application of *Low-Materiality Fees Regulations*

Not subject to *Service Fees Act*: New Active Substance

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
New Active Substance	590,346	22,891,247	601,391	April 1, 2026	616,593

Fee

Clinical or non-clinical data and chemistry and manufacturing data

Fee-setting authority

- *Food and Drugs Act (FDA)*, 30.61(1)
- *Fees in Respect of Drugs and Medical Devices Order* (SOR/2019-124)

Year fee-setting authority was introduced

2017

Last year fee-setting authority was amended

2025

Service standard

- For drugs under Division 1 of the Food and Drug Regulations: 210 calendar days to complete Review 1
- For drugs under Division 8 of the Food and Drug Regulations: 300 calendar days to complete Review 1

Performance result

- 210 calendar days – 100% (1/1 completed within service standard)
- 300 calendar days – 97.8% (45/46 completed within service standard)

Application of *Low-Materiality Fees Regulations*

Not subject to *Service Fees Act*: Clinical or non-clinical data and chemistry and manufacturing data

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
Clinical or non-clinical data and chemistry and manufacturing data	305,690	20,092,904	439,209	April 1, 2026	319,282

Fee

Clinical or non-clinical data only

Fee-setting authority

- *Food and Drugs Act (FDA)*, 30.61(1)
- *Fees in Respect of Drugs and Medical Devices Order* (SOR/2019-124)

Year fee-setting authority was introduced

2017

Last year fee-setting authority was amended

2025

Service standard

- For drugs under Division 1 of the Food and Drug Regulations: 210 calendar days to complete Review 1
- For drugs under Division 8 of the Food and Drug Regulations: 300 calendar days to complete Review 1

Performance result

- 210 calendar days – 100% (1/1 completed within service standard)
- 300 calendar days – 95.6% (130/136 completed within service standard)

Application of *Low-Materiality Fees Regulations*

Not subject to *Service Fees Act*: Clinical or non-clinical data only

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
Clinical or non-clinical data only	122,232	14,593,923	263,430	April 1, 2026	127,668

Fee

Comparative studies

Fee-setting authority

- *Food and Drugs Act (FDA)*, 30.61(1)
- *Fees in Respect of Drugs and Medical Devices Order* (SOR/2019-124)

Year fee-setting authority was introduced

2017

Last year fee-setting authority was amended

2025

Service standard

- For drugs under Division 1 of the Food and Drug Regulations: 210 calendar days to complete Review 1
- For drugs under Division 8 of the Food and Drug Regulations: 180 calendar days to complete Review 1

Performance result

- 210 calendar days – 100% (6/6 completed within service standard)
- 180 calendar days – 95.8% (182/190 completed within service standard)

Application of *Low-Materiality Fees Regulations*

Not subject to *Service Fees Act*: Comparative studies

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
Comparative studies	68,889	11,655,021	73,449	April 1, 2026	71,953

Fee

Chemistry and manufacturing data only

Fee-setting authority

- *Food and Drugs Act (FDA)*, 30.61(1)
- *Fees in Respect of Drugs and Medical Devices Order* (SOR/2019-124)

Year fee-setting authority was introduced

2017

Last year fee-setting authority was amended

2025

Service standard

- For drugs under Division 1 of the Food and Drug Regulations: 210 calendar days to complete Review 1
- For drugs under Division 8 of the Food and Drug Regulations: 180 calendar days to complete Review 1

Performance result

- 210 calendar days – 80% (36/45 completed within service standard)
- 180 calendar days – 95.3% (345/362 completed within service standard)

Application of *Low-Materiality Fees Regulations*

Not subject to *Service Fees Act*: Chemistry and manufacturing data only

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
Chemistry and manufacturing data only	42,384	16,742,891	335,271	April 1, 2026	44,269

Fee

Clinical or non-clinical data only, in support of safety upgrades to the labelling

Fee-setting authority

- *Food and Drugs Act (FDA)*, 30.61(1)
- *Fees in Respect of Drugs and Medical Devices Order* (SOR/2019-124)

Year fee-setting authority was introduced

2017

Last year fee-setting authority was amended

2025

Service standard

120 calendar days to complete Review 1

Performance result

99.5% (217/218 completed within service standard)

Application of *Low-Materiality Fees Regulations*

Not subject to *Service Fees Act*: Clinical or non-clinical data only, in support of safety upgrades to the labelling

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
Clinical or non-clinical data only, in support of safety upgrades to the labelling	22,372	5,075,649	0	April 1, 2026	23,368

Fee

Labelling only

Fee-setting authority

- *Food and Drugs Act (FDA)*, 30.61(1)
- *Fees in Respect of Drugs and Medical Devices Order* (SOR/2019-124)

Year fee-setting authority was introduced

2017

Last year fee-setting authority was amended

2025

Service standard

120 calendar days to complete Review 1

Performance result

99.4% (655/659 completed within service standard)

Application of *Low-Materiality Fees Regulations*

Not subject to *Service Fees Act*: Labelling only

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
Labelling only	6,161	3,744,919	6,769	April 1, 2026	6,436

Fee

Labelling only (generic drugs)

Fee-setting authority

- *Food and Drugs Act (FDA)*, 30.61(1)
- *Fees in Respect of Drugs and Medical Devices Order* (SOR/2019-124)

Year fee-setting authority was introduced

2017

Last year fee-setting authority was amended

2025

Service standard

120 calendar days to complete Review 1

Performance result

100% (221/221 completed within service standard)

Application of *Low-Materiality Fees Regulations*

Not subject to *Service Fees Act*: Labelling only (generic drugs)

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
Labelling only (generic drugs)	2,315	436,077	0	April 1, 2026	2,419

Fee

Administrative submission

Fee-setting authority

- *Food and Drugs Act (FDA)*, 30.61(1)
- *Fees in Respect of Drugs and Medical Devices Order* (SOR/2019-124)

Year fee-setting authority was introduced

2017

Last year fee-setting authority was amended

2025

Service standard

45 calendar days to review

Performance result

98.7% (597/605 completed within service standard)

Application of *Low-Materiality Fees Regulations*

Not subject to *Service Fees Act*: Administrative submission

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
Administrative submission	975	537,836	1,166	April 1, 2026	1,020

Fee

Disinfectant - full review

Fee-setting authority

- *Food and Drugs Act (FDA)*, 30.61(1)
- *Fees in Respect of Drugs and Medical Devices Order* (SOR/2019-124)

Year fee-setting authority was introduced

2017

Last year fee-setting authority was amended

2025

Service standard

- For drugs under Division 1 of the Food and Drug Regulations: 210 calendar days to complete Review 1
- For drugs under Division 8 of the Food and Drug Regulations: 300 calendar days to complete Review 1

Performance result

- 210 calendar days – 62.1% (36/58 completed within service standard)
- 300 calendar days - 50% (2/4 completed within service standard)

Application of *Low-Materiality Fees Regulations*

Not subject to *Service Fees Act*: Disinfectant - full review

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
Disinfectant - full review	12,839	198,093	21,520	April 1, 2026	13,411

Fee

Labelling only (disinfectants)

Fee-setting authority

- *Food and Drugs Act (FDA)*, 30.61(1)
- *Fees in Respect of Drugs and Medical Devices Order* (SOR/2019-124)

Year fee-setting authority was introduced

2017

Last year fee-setting authority was amended

2025

Service standard

90 calendar days to complete Review 1

Performance result

68.2% (15/22 completed within service standard)

Application of *Low-Materiality Fees Regulations*

Not subject to *Service Fees Act*: Labelling only (disinfectants)

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
Labelling only (disinfectants)	2,886	45,212	691	April 1, 2026	3,015

Fee

Drug identification number application - labelling standards

Fee-setting authority

- *Food and Drugs Act (FDA)*, 30.61(1)
- *Fees in Respect of Drugs and Medical Devices Order* (SOR/2019-124)

Year fee-setting authority was introduced

2017

Last year fee-setting authority was amended

2025

Service standard

60 calendar days to complete Review 1

Performance result

96.8% (122/126 completed within service standard)

Application of *Low-Materiality Fees Regulations*

Not subject to *Service Fees Act*: Drug identification number application - labelling standards

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
Drug identification number application - labelling standards	1,861	208,672	1,589	April 1, 2026	1,945

Certificate of Supplementary Protection Application Fees

In agreeing to provisionally apply the Canada-European Union Comprehensive Economic and Trade Agreement (CETA), Canada has committed to provide up to two years of sui generis (of its own kind) protection for new pharmaceutical products protected by an eligible patent, from the expiry of the patent. Canada has implemented this commitment by introducing Certificates of Supplementary Protection (CSPs) for medicinal ingredients, applicable for Canadian pharmaceuticals, biologics and veterinary drugs.

Fee

Certificate of Supplementary Protection Application Fees

Fee-setting authority

- *Patent Act*, 134(1)
- *Certificate of Supplementary Protection Regulations* (SOR/2017-165)

Year fee-setting authority was introduced

2017

Last year fee-setting authority was amended

2025

Service standard

60 days for the first eligibility decision

Performance result

100% (16/16 completed within service standard)

Application of *Low-Materiality Fees Regulations*

Not subject to *Service Fees Act*: Certificate of Supplementary Protection Application Fees

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
Certificate of Supplementary Protection Application Fees	10,356	103,560	This fee was not subject to remissions	April 1, 2026	10,776

Master File Fees

A Master File (MF) is a reference that provides information about specific processes or components used in the manufacturing, processing, or packaging of a drug. The MF is a useful vehicle for providing information to Health Canada, where that information is confidential business information (CBI) and is not available to the manufacturer of the dosage form or to the sponsors of a drug submission, DIN (Drug identification Number) application or clinical trial application (CTA).

Fee

- New Master Files (file registration)
- Drug Master Files - letter of access
- Drug Master Files - Update

Fee-setting authority

- Minister's Authority
- Fees notice published in [Canada Gazette](#)

Year fee-setting authority was introduced

1996

Last year fee-setting authority was amended

2017

Service standard

30 calendar days

Performance result

100% (2,245/2,245 issued within 30 calendar days)

Application of *Low-Materiality Fees Regulations*

Not subject to section 17 of the *Service Fees Act*: All fees listed below

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
New Master Files (file registration)	1,379	326,116	This fee was not	April 1, 2026	1,436

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
Drug Master Files – letter of access	196	255,613	subject to remissions	April 1, 2026	204
Drug Master Files - Update	599	432,584		April 1, 2026	624

Fees for Right to Sell Drugs – Human Use

Health Canada monitors human drugs on the Canadian market through post-market surveillance and compliance and enforcement activities. Industry pays an annual fee for the right to maintain and sell human drugs in Canada.

Fee

- Human drugs - Disinfectant (item 1)
- Human drugs - Non-prescription (item 2)
- Human drugs - Prescription (drug other than one referred to in item 1 or 2)

Fee-setting authority

- *Food and Drugs Act (FDA)*, 30.61(1)
- *Fees in Respect of Drugs and Medical Devices Order* (SOR/2019-124)

Year fee-setting authority was introduced

2017

Last year fee-setting authority was amended

2025

Service standard

20 calendar days to update the Drug Product Database following receipt of a complete Annual Notification Package

Performance result

100% (1,098/1,098 human and veterinary completed within service standard)

Application of *Low-Materiality Fees Regulations*

Not subject to *Service Fees Act*: All fees listed below

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
Human drugs - Disinfectant (item 1)	1,684	1,510,155	0	April 1, 2026	1,760
Human drugs - Non-prescription (item 2)	3,246	7,921,878	0	April 1, 2026	3,391

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
Human drugs - Prescription (drug other than one referred to in item 1 or 2)	5,385	45,965,950	0	April 1, 2026	5,626

Drug Establishment Licensing Fees – Human Use

Any person in Canada must obtain a Drug Establishment Licence (DEL) if they are engaged in any of the six regulated activities (fabricate, import, distribute, wholesale, package/label, and test) with respect to human drugs. A fee is charged for the examination of a DEL application, including all compliance and enforcement and supporting activities needed to ensure that the applicant/licence holder conforms to all regulatory requirements. The DEL fee is calculated on a per-site basis, therefore, the fee amount varies by application. A DEL fee is charged for the application for a new DEL, an annual licence review of a DEL, certain amendments to a DEL, or reinstatement of a suspended DEL.

Fee

Human Drug Establishment Licence Fees

Fee-setting authority

- *Food and Drugs Act (FDA)*, 30.61(1)
- *Fees in Respect of Drugs and Medical Devices Order* (SOR/2019-124)

Year fee-setting authority was introduced

2017

Last year fee-setting authority was amended

2025

Service standard

250 calendar days to issue/ renew license

Performance result

100% (791/791) of licences issued (human and veterinary) within 250 calendar days

Application of *Low-Materiality Fees Regulations*

Not subject to *Service Fees Act*: All fees listed below

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
Fabrication - Sterile dosage form	48,255	2,138,201	0	April 1, 2026	50,401

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
Importation	37,259	12,209,699	0	April 1, 2026	38,916
Fabrication - non-sterile dosage form	35,774	2,237,165	0	April 1, 2026	37,365
Distribution	19,017	918,856	0	April 1, 2026	19,864
Wholesaling	11,098	1,339,544	0	April 1, 2026	11,592
Packaging/labelling	6,975	598,860	0	April 1, 2026	7,286
Testing	5,757	326,466	0	April 1, 2026	6,014
Building outside Canada (each)	1,059	13,044,476	0	April 1, 2026	1,107

Certificate of Pharmaceutical Product Fee

A certificate issued establishing the status of the pharmaceutical, biological, radiopharmaceutical or veterinary product listed and the Good Manufacturing Practice status of the fabricator of the product.

Fee

Certificate of Pharmaceutical Product

Fee-setting authority

- Minister's Authority
- Fees notice published in [Canada Gazette](#)

Year fee-setting authority was introduced

1996

Last year fee-setting authority was amended

2012

Service standard

25 business days to issue certificate

Performance result

94.8% (2,409/2,541 of certificates issued within 25 business days)

Application of *Low-Materiality Fees Regulations*

Not subject to section 17 of the *Service Fees Act*: Certificate of Pharmaceutical Product

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
Certificate of Pharmaceutical Product	100	242,509	This fee was not subject to remissions	April 1, 2026	105

Fees for Examination of a Submission – Drugs for Veterinary Use Only

Before a veterinary drug is authorized for sale in Canada, Health Canada reviews it to assess its efficacy and safety in the intended species as well as human safety. Fees are calculated on a component basis.

Fee

Drug Identification Number (Schedule 2 items 1 to 3)

Fee-setting authority

- *Food and Drugs Act (FDA)*, 30.61(1)
- *Fees in Respect of Drugs and Medical Devices Order* (SOR/2019-124)

Year fee-setting authority was introduced

2017

Last year fee-setting authority was amended

2025

Service standard

120 calendar days to complete Review 1

Performance result

100% (18/18 completed within service standard)

Application of *Low-Materiality Fees Regulations*

Not subject to *Service Fees Act*: All fees listed below

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
1) Information, other than that referred to in item 2, to support an application for a number, including the submission of labelling material for a second review, if required	2,257	4,514	0	April 1, 2026	2,946

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
2) Published references or other data	1,569	0	0	April 1, 2026	2,047
3) Documentation to support a change of manufacturer, a change to the name of a manufacturer or a change to the brand name of a drug	786	393	0	April 1, 2026	1,025

Fee

Notification - veterinary health product (Schedule 2 item 4)

Fee-setting authority

- *Food and Drugs Act (FDA)*, 30.61(1)
- *Fees in Respect of Drugs and Medical Devices Order* (SOR/2019-124)

Year fee-setting authority was introduced

2017

Last year fee-setting authority was amended

2025

Service standard

30 calendar days to process notification

Performance result

100% (634/634 completed within service standard)

Application of *Low-Materiality Fees Regulations*

Not subject to *Service Fees Act*: All fees listed below

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
4) Information contained in a notification filed under subsection C.01.615(1) of the Food and Drug Regulations in respect of a veterinary health product	562	172,824	0	April 1, 2026	588

Fee

New drug submission (Schedule 2 items 5 to 18)

Fee-setting authority

- *Food and Drugs Act (FDA)*, 30.61(1)
- *Fees in Respect of Drugs and Medical Devices Order* (SOR/2019-124)

Year fee-setting authority was introduced

2017

Last year fee-setting authority was amended

2025

Service standard

- 300 calendar days to complete Review 1 (items 5 to 17)
- 90 calendar days to complete Review 1 (item 18)

Performance result

- 300 calendar days - 100% (9/9 completed within service standard)
- 90 calendar days - 100% (1/1 completed within service standard)

Application of *Low-Materiality Fees Regulations*

Not subject to *Service Fees Act*: All fees listed below

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
5) Efficacy and safety data (in the intended species) to support a single route of administration, dosage form and indication in one animal species. (In the case of an antiparasitic drug, several indications in one food animal species.)	50,015	417,030	0	April 1, 2026	65,297

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
6) Efficacy and safety data (in the intended species) to support a single route of administration and dosage form for an antiparasitic drug in one non-food animal species	30,298	30,298	0	April 1, 2026	39,557
7) Efficacy and safety data (in the intended species) to support a single route of administration, dosage form and indication in two animal species, or a single route of administration, dosage form and two indications in one animal species	72,735	0	0	April 1, 2026	94,961
8) Efficacy and safety data (in the intended species) to support a growth promotion or production enhancement indication in one animal species	98,491	0	0	April 1, 2026	128,589
9) Comparative (pharmacodynamics, clinical or bioavailability) data to support an additional route of administration	9,079	0	0	April 1, 2026	11,855
10) Comparative (pharmacodynamics, clinical or bioavailability) data to support each additional strength	1,505	0	0	April 1, 2026	1,964
11) For food-producing animals, toxicity, metabolism and residue depletion studies to establish an acceptable daily intake with a safety factor of 1,000, a maximum residue limit and a withdrawal period for a single dosage form, dosage and route of administration in one species	68,199	68,199	0	April 1, 2026	89,035

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
12) For food-producing animals, toxicity, metabolism and residue depletion studies to establish an acceptable daily intake with a safety factor of less than 1,000, a maximum residue limit and a withdrawal period for a single dosage form, dosage and route of administration in one species	90,918	90,918	0	April 1, 2026	118,700
13) For food-producing animals, residue depletion studies to establish a withdrawal period for an additional dosage form, dosage or route of administration	9,079	4,540	0	April 1, 2026	11,855
14) For food-producing animals (once an acceptable daily intake with a safety factor of 1,000 or less has been established), metabolism and residue depletion studies to establish a maximum residue limit and a withdrawal period for a single dosage form, dosage and route of administration in an additional species	45,446	0	0	April 1, 2026	59,332
15) Chemistry and manufacturing data for a non-compendial medicinal ingredient of a drug	15,150	128,775	0	April 1, 2026	19,780
16) Chemistry and manufacturing data to support one strength of a single dosage form	15,150	141,472	0	April 1, 2026	19,780
17) Chemistry and manufacturing data to support an additional strength of a single dosage form submitted at the same time as item 16	7,578	37,890	0	April 1, 2026	9,893

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
18) Documentation to support a change of manufacturer	786	786	0	April 1, 2026	1,025

Fee

Supplement to a new drug submission (Schedule 2 items 19 to 37)

Fee-setting authority

- *Food and Drugs Act (FDA)*, 30.61(1)
- *Fees in Respect of Drugs and Medical Devices Order* (SOR/2019-124)

Year fee-setting authority was introduced

2017

Last year fee-setting authority was amended

2025

Service standard

- 240 calendar days to complete Review 1 (items 19 to 36)
- 90 calendar days to complete Review 1 (item 37)

Performance result

- 240 calendar days - 100% (13/13 completed within service standard)
- 90 calendar days – 100% (2/2 completed within service standard)

Application of *Low-Materiality Fees Regulations*

Not subject to *Service Fees Act*: All fees listed below

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
19) Efficacy data to support an additional indication in one animal species	39,406	78,812	0	April 1, 2026	51,445
20) Efficacy and safety data (in the intended species) to support a single route of administration and dosage form for an antiparasitic drug in one non-food animal species	30,298	146,584	0	April 1, 2026	39,557

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
21) Efficacy and safety data (in the intended species) to support an indication in another animal species	50,015	0	0	April 1, 2026	65,297
22) Efficacy and safety data (in the intended species) to support a single route of administration, dosage form and indication in two animal species, or a single route of administration and dosage form and two indications in one animal species.	72,735	0	0	April 1, 2026	94,961
23) Efficacy and safety data (in the intended species) to support a growth promotion or production enhancement indication in one animal species	98,491	0	0	April 1, 2026	128,589
24) Efficacy and safety data (in the intended species) to support the concurrent use of two drugs approved for the same animal species	24,225	0	0	April 1, 2026	31,628
25) Comparative (pharmacodynamics, clinical or bioavailability) data to support an additional route of administration	9,079	0	0	April 1, 2026	11,855
26) Comparative (pharmacodynamics, clinical or bioavailability) data to support each additional strength	1,505	1,261	0	April 1, 2026	1,964
27) For food-producing animals, residue depletion studies to establish a new withdrawal period for a change in the dosage or route of administration of an approved dosage form in one species	9,079	0	0	April 1, 2026	11,855

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
28) For food-producing animals, metabolism and residue depletion studies to establish a maximum residue limit and a withdrawal period for a single dosage and route of administration of an approved dosage form in an additional species	45,446	0	0	April 1, 2026	59,332
29) For food-producing animals, toxicity studies to support a change of an established acceptable daily intake, maximum residue limit and withdrawal period	22,724	0	0	April 1, 2026	29,667
30) For the concurrent use of two drugs in a species of food-producing animals, residue depletion studies to determine if an extension to existing withdrawal periods is required	18,187	0	0	April 1, 2026	23,744
31) Chemistry and manufacturing data to support a change in the source of a medicinal ingredient or its manufacturing process	15,150	0	0	April 1, 2026	19,780
32) Chemistry and manufacturing data to support a change in formulation or dosage form	7,578	6,350	0	April 1, 2026	9,893
33) Chemistry and manufacturing data to support a change in packaging or in the sterilization process	6,043	6,043	0	April 1, 2026	7,888
34) Chemistry and manufacturing data to support an extension of the expiry dating	4,541	0	0	April 1, 2026	5,930

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
35) Chemistry and manufacturing data to support the concurrent use of two drugs	4,541	0	0	April 1, 2026	5,930
36) Chemistry and manufacturing data to support a change in the manufacturing site for parenteral dosage forms	1,505	0	0	April 1, 2026	1,964
37) Documentation to support a change to the name of a manufacturer or the brand name of a drug	786	0	0	April 1, 2026	1,025

Fee

Abbreviated new drug submission (Schedule 2 items 38 to 42)

Fee-setting authority

- *Food and Drugs Act (FDA)*, 30.61(1)
- *Fees in Respect of Drugs and Medical Devices Order* (SOR/2019-124)

Year fee-setting authority was introduced

2017

Last year fee-setting authority was amended

2025

Service standard

- 300 calendar days to complete Review (items 38 to 41)
- 90 calendar days to complete Review 1 (item 42)

Performance result

- 300 calendar days - 100% (4/4 completed within service standard)
- 90 calendar days – 100% (2/2 completed within service standard)

Application of *Low-Materiality Fees Regulations*

Not subject to *Service Fees Act*: All fees listed below

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
38) Comparative (pharmacodynamics, clinical or bioavailability) data to support a single route of administration and dosage form	9,079	16,689	0	April 1, 2026	11,855
39) For food-producing animals, residue depletion studies to confirm that the withdrawal period(s) for each species falls within the conditions of use for the Canadian reference product	9,079	0	0	April 1, 2026	11,855

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
40) Chemistry and manufacturing data for a non-compendial medicinal ingredient of a drug	15,150	63,269	0	April 1, 2026	19,780
41) Chemistry and manufacturing data to support a single dosage form	15,150	85,994	0	April 1, 2026	19,780
42) Documentation to support (a) a change of manufacturer, in the case of an abbreviated new drug submission; or (b) a change to the name of a manufacturer or the brand name of a drug, in the case of a supplement to an abbreviated new drug submission	786	1,572	0	April 1, 2026	1,025

Fee

Supplement to an abbreviated new drug submission (Schedule 2 items 38 to 42)

Fee-setting authority

- *Food and Drugs Act (FDA)*, 30.61(1)
- *Fees in Respect of Drugs and Medical Devices Order* (SOR/2019-124)

Year fee-setting authority was introduced

2017

Last year fee-setting authority was amended

2025

Service standard

- 240 calendar days to complete Review 1 (items 38 to 41)
- 90 calendar days to complete Review 1 (item 42)

Performance result

- 240 calendar days - 100% (3/3 completed within service standard)
- 90 calendar days - 100% (1/1 completed within service standard)

Application of *Low-Materiality Fees Regulations*

Not subject to *Service Fees Act*: All fees listed below

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
38) Comparative (pharmacodynamics, clinical or bioavailability) data to support a single route of administration and dosage form	9,079	16,689	0	April 1, 2026	11,855
39) For food-producing animals, residue depletion studies to confirm that the withdrawal period(s) for each species falls within the conditions of use for the Canadian reference product	9,079	0	0	April 1, 2026	11,855

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
40) Chemistry and manufacturing data for a non-compendial medicinal ingredient of a drug	15,150	63,269	0	April 1, 2026	19,780
41) Chemistry and manufacturing data to support a single dosage form	15,150	85,994	0	April 1, 2026	19,780
42) Documentation to support (a) a change of manufacturer, in the case of an abbreviated new drug submission; or (b) a change to the name of a manufacturer or the brand name of a drug, in the case of a supplement to an abbreviated new drug submission	786	1,572	0	April 1, 2026	1,025

Fee

Preclinical submission (Schedule 2 items 43 to 50)

Fee-setting authority

- *Food and Drugs Act (FDA)*, 30.61(1)
- *Fees in Respect of Drugs and Medical Devices Order* (SOR/2019-124)

Year fee-setting authority was introduced

2017

Last year fee-setting authority was amended

2025

Service standard

60 calendar days to complete Review 1

Performance result

Not applicable - no applications received

Application of *Low-Materiality Fees Regulations*

Not subject to *Service Fees Act*: All fees listed below

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
43) Efficacy and safety data (in the intended species) and protocol to support the conduct of clinical studies relative to a single dose form, route of administration and indication in one species	15,150	0	0	April 1, 2026	19,780

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
44) Efficacy data and protocol to support the conduct of clinical studies relative to a single route of administration and indication with a dosage form for which a notice of compliance has been issued for use in the species to be treated	12,114	0	0	April 1, 2026	15,816
45) For food-producing animals, toxicity, metabolism and residue depletion studies to establish a temporary acceptable daily intake, a maximum residue limit and a withdrawal period for a single dosage form, dosage and route of administration in one species	45,446	0	0	April 1, 2026	59,332
46) For food-producing animals, toxicity, metabolism and residue depletion studies to establish an acceptable daily intake with a safety factor of 1,000, a maximum residue limit and a withdrawal period for a single dosage form, dosage and route of administration in one species	68,199	0	0	April 1, 2026	89,035
47) For food-producing animals, toxicity, metabolism and residue depletion studies to establish an acceptable daily intake with a safety factor of less than 1,000, a maximum residue limit and a withdrawal period for a single dosage form, dosage and route of administration in one species	90,918	0	0	April 1, 2026	118,700

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
48) For food-producing animals (once an acceptable daily intake with a safety factor of 1,000 or less has been established), metabolism studies to establish a withdrawal period for a single dosage form, dosage and route of administration in an additional species	22,724	0	0	April 1, 2026	29,667
49) Chemistry and manufacturing data to support a single dosage form containing a non-compendial medicinal ingredient	15,150	0	0	April 1, 2026	19,780
50) Chemistry and manufacturing data to support a single dosage form containing a compendial medicinal ingredient	7,578	0	0	April 1, 2026	9,893

Fee

Sale of new drug for emergency treatment (Schedule 2 items 51 and 52)

Fee-setting authority

- *Food and Drugs Act (FDA)*, 30.61(1)
- *Fees in Respect of Drugs and Medical Devices Order* (SOR/2019-124)

Year fee-setting authority was introduced

2017

Last year fee-setting authority was amended

2025

Service standard

2 business days to review application

Performance result

100% (630/630 completed within service standard)

Application of *Low-Materiality Fees Regulations*

Not subject to *Service Fees Act*: All fees listed below

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
51) Information to support the sale of a drug to be used in the emergency treatment of a non-food-producing animal	60	25,551	0	April 1, 2026	64
52) Information to support the sale of a drug to be used in the emergency treatment of a food-producing animal	120	9,615	0	April 1, 2026	127

Fee

Experimental studies certificate (Schedule 2 items 53 to 56)

Fee-setting authority

- *Food and Drugs Act (FDA)*, 30.61(1)
- *Fees in Respect of Drugs and Medical Devices Order* (SOR/2019-124)

Year fee-setting authority was introduced

2017

Last year fee-setting authority was amended

2025

Service standard

60 calendar days to review application

Performance result

100% (100/100 completed within service standard)

Application of *Low-Materiality Fees Regulations*

Not subject to *Service Fees Act*: All fees listed below

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
53) Information and material to support the issuance of an experimental studies certificate for a drug to be administered to a non-food-producing animal	1,130	15,465	0	April 1, 2026	1,181
54) Information and material to support the issuance of an experimental studies certificate whose protocol is the same as that for a previously authorized experimental studies certificate for a drug to be administered to a non-food-producing animal	566	1,131	0	April 1, 2026	592

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
55) Information and material to support the issuance of an experimental studies certificate for a drug to be administered to a food-producing animal	3,406	11,921	0	April 1, 2026	3,558
56) Information and material to support the issuance of an experimental studies certificate whose protocol is the same as that for a previously authorized experimental studies certificate for a drug to be administered to a food-producing animal	566	566	0	April 1, 2026	592

Fee

Notifiable change (Schedule 2 item 57)

Fee-setting authority

- *Food and Drugs Act (FDA)*, 30.61(1)
- *Fees in Respect of Drugs and Medical Devices Order* (SOR/2019-124)

Year fee-setting authority was introduced

2017

Last year fee-setting authority was amended

2025

Service standard

90 calendar days to review application

Performance result

100% (41/41 completed within service standard)

Application of *Low-Materiality Fees Regulations*

Not subject to *Service Fees Act*: All fees listed below

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
57) Information and material to support an application for Notifiable Change	4,072	101,200	0	April 1, 2026	5,316

Fee

Protocol (Schedule 2 item 58)

Fee-setting authority

- *Food and Drugs Act (FDA)*, 30.61(1)
- *Fees in Respect of Drugs and Medical Devices Order* (SOR/2019-124)

Year fee-setting authority was introduced

2017

Last year fee-setting authority was amended

2025

Service standard

90 calendar days to review package

Performance result

Not applicable - no applications received

Application of *Low-Materiality Fees Regulations*

Not subject to *Service Fees Act*: All fees listed below

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
58) A protocol that is filed with the Minister and may support a new drug submission, an abbreviated new drug submission, a supplement to a new drug submission or abbreviated new drug submission, a preclinical submission or information and material that is filed for the purpose of obtaining an experimental studies certificate	4,072	0	0	April 1, 2026	5,316

Fees for Right to Sell Drugs – Veterinary Use

Health Canada monitors veterinary drugs on the Canadian market through post-market surveillance and compliance and enforcement activities. Industry pays an annual fee for the right to maintain veterinary drugs in Canada.

Fee

Veterinary Drugs

Fee-setting authority

- *Food and Drugs Act (FDA)*, 30.61(1)
- *Fees in Respect of Drugs and Medical Devices Order* (SOR/2019-124)

Year fee-setting authority was introduced

2017

Last year fee-setting authority was amended

2025

Service standard

20 calendar days to update the Drug Product Database following receipt of a complete Annual Notification Package

Performance result

100% (1,098/1,098 human and veterinary completed within the service standard)

Application of *Low-Materiality Fees Regulations*

Not subject to *Service Fees Act*: Veterinary Drugs

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
Veterinary Drugs	552	468,394	0	April 1, 2026	577

Drug Establishment Licensing Fees – Veterinary Use

Any person in Canada must obtain a Drug Establishment Licence (DEL) if they are engaged in any of the six regulated activities (fabricate, import, distribute, wholesale, package/label, and test) with respect to veterinary drugs. A fee is charged for the examination of a DEL application, including all compliance and enforcement and supporting activities needed to ensure that the applicant/licence holder conforms to all regulatory requirements. The DEL fee is calculated on a per-site basis, therefore, the fee amount varies by application. A DEL fee is charged for the application for a new DEL, an annual licence review of a DEL, certain amendments to a DEL, or reinstatement of a suspended DEL.

Fee

Veterinary Drug Establishment Licence Fees

Fee-setting authority

- *Food and Drugs Act (FDA)*, 30.61(1)
- *Fees in Respect of Drugs and Medical Devices Order* (SOR/2019-124)

Year fee-setting authority was introduced

2017

Last year fee-setting authority was amended

2025

Service standard

250 calendar days to issue/ renew license

Performance result

100% (791/791) of licences issued (human and veterinary) within 250 calendar days

Application of *Low-Materiality Fees Regulations*

Not subject to *Service Fees Act*: All fees listed below

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
Fabrication - Sterile dosage form	47,588	0	0	April 1, 2026	50,401
Importation	30,099	629,120	0	April 1, 2026	38,916

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
Fabrication - non-sterile dosage form	24,671	61,441	0	April 1, 2026	37,365
Distribution	13,583	48,778	0	April 1, 2026	19,864
Wholesaling	5,431	73,210	0	April 1, 2026	8,864
Packaging/labelling	6,975	0	0	April 1, 2026	7,286
Testing	3,695	2,771	0	April 1, 2026	6,014
Building outside Canada (each)	1,059	825,585	0	April 1, 2026	1,107

Drug Establishment Licensing Fees - Dealer's Licences

Fees for the examination of a new dealer's licence application (Human Drugs), a new dealer's licence (Veterinary Drugs) or the renewal of a dealer's licence; issued under the Narcotic Control Regulations and Part G of the Food and Drug Regulations. There is no fee associated with the application for a new or renewal of a controlled substances licence issued under the Benzodiazepines and Other Targeted Substances Regulations and Part J of the Food and Drug Regulations.

Fee

- Dealer's Licence Fees - Human Drugs
- Dealer's Licence Fees - Veterinary Drugs

Fee-setting authority

Financial Administration Act (FAA)

- Human Drugs: *Fees in Respect of a Dealer's Licences Regulations* (SOR/2011-79)
- Veterinary Drugs: *Licensed Dealers for Controlled Drugs and Narcotics (Veterinary Use) Fees Regulations* (SOR/98-5)

Year fee-setting authority was introduced

1998

Last year fee-setting authority was amended

- Human Drugs: 2020
- Veterinary Drugs: 2022

Service standard:

- 270 Calendar days to issue a decision on an application for a **new** dealer's licence for controlled substances, from the receipt of a complete application
- 90 Calendar days to issue a decision on an application to **renew** a dealer's licence for controlled substances, from the receipt of a complete application

Performance result

- **New:** 92.9% (39/42) of applications were processed within the service standard
- **Renew:** 99.5% (186/187) of applications were processed within the service standard

Application of *Low-Materiality Fees Regulations*

Material (>\$151): All fees listed below

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
Dealer's Licence Fees - Human Drugs	5,841.00	476,782	11,143	April 1, 2026	6,078.00
Dealer's Licence Fees - Veterinary Drugs	2,098.99	8,080	228	April 1, 2026	2,192.31
Dealer's Licence Fees - Veterinary Drugs – First Year	1,049.50	1,916	0	April 1, 2026	1,096.16

Fees for Examination of an Application for a Medical Device Licence

The Medical Device Licence Application Fees apply only to Class II, III and IV medical device licence applications. The following types of medical devices are exempt from medical device licensing and therefore no fees apply: Class I medical devices; custom-made medical devices; medical devices for special access; and medical devices for investigational testing involving human subjects.

Fee

Applications for Class II licence

Fee-setting authority

- *Food and Drugs Act (FDA), 30.61(1)*
- *Fees in Respect of Drugs and Medical Devices Order (SOR/2019-124)*

Year fee-setting authority was introduced

2017

Last year fee-setting authority was amended

2025

Service standard

15 calendar days to review

Performance result

99.3% (1,528/1,539 completed within service standard)

Application of *Low-Materiality Fees Regulations*

Not subject to *Service Fees Act*: Applications for Class II licence

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
Applications for Class II licence	615	847,004	1,384	April 1, 2026	643

Fee

Applications for Class II licence amendment

Fee-setting authority

- *Food and Drugs Act (FDA)*, 30.61(1)
- *Fees in Respect of Drugs and Medical Devices Order* (SOR/2019-124)

Year fee-setting authority was introduced

2017

Last year fee-setting authority was amended

2025

Service standard

15 calendar days to review

Performance result

99.2% (1,344/1,355 completed within service standard)

Application of *Low-Materiality Fees Regulations*

Not subject to *Service Fees Act*: Applications for Class II licence amendment

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
Applications for Class II licence amendment	316	394,014	546	April 1, 2026	331

Fee

Applications for Class III licence

Fee-setting authority

- *Food and Drugs Act (FDA)*, 30.61(1)
- *Fees in Respect of Drugs and Medical Devices Order* (SOR/2019-124)

Year fee-setting authority was introduced

2017

Last year fee-setting authority was amended

2025

Service standard

60 calendar days to complete Review 1

Performance result

99.7% (302/303 completed within service standard)

Application of *Low-Materiality Fees Regulations*

Not subject to *Service Fees Act*: Applications for Class III licence

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
Applications for Class III licence	13,559	3,503,741	0	April 1, 2026	14,163

Fee

Applications for Class III licence (near patient)

Fee-setting authority

- *Food and Drugs Act (FDA)*, 30.61(1)
- *Fees in Respect of Drugs and Medical Devices Order* (SOR/2019-124)

Year fee-setting authority was introduced

2017

Last year fee-setting authority was amended

2025

Service standard

60 calendar days to complete Review 1

Performance result

100% (12/12 completed within service standard)

Application of *Low-Materiality Fees Regulations*

Not subject to *Service Fees Act*: Applications for Class III licence (near patient)

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
Applications for Class III licence (near patient)	28,884	315,619	0	April 1, 2026	30,169

Fee

Applications for Class III licence amendment - changes in manufacturing

Fee-setting authority

- *Food and Drugs Act (FDA)*, 30.61(1)
- *Fees in Respect of Drugs and Medical Devices Order* (SOR/2019-124)

Year fee-setting authority was introduced

2017

Last year fee-setting authority was amended

2025

Service standard

60 calendar days to complete Review 1

Performance result

100% (28/28 completed within service standard)

Application of *Low-Materiality Fees Regulations*

Not subject to *Service Fees Act*: Applications for Class III licence amendment - changes in manufacturing

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
Applications for Class III licence amendment - changes in manufacturing	4,279	73,035	0	April 1, 2026	4,470

Fee

Applications for Class III licence amendment - significant changes not related to manufacturing

Fee-setting authority

- *Food and Drugs Act (FDA)*, 30.61(1)
- *Fees in Respect of Drugs and Medical Devices Order* (SOR/2019-124)

Year fee-setting authority was introduced

2017

Last year fee-setting authority was amended

2025

Service standard

60 calendar days to complete Review 1

Performance result

100% (353/353 completed within service standard)

Application of *Low-Materiality Fees Regulations*

Not subject to *Service Fees Act*: Applications for Class III licence amendment - significant changes not related to manufacturing

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
Applications for Class III licence amendment - significant changes not related to manufacturing	10,884	3,720,579	533	April 1, 2026	11,369

Fee

Applications for Class IV licence

Fee-setting authority

- *Food and Drugs Act (FDA)*, 30.61(1)
- *Fees in Respect of Drugs and Medical Devices Order* (SOR/2019-124)

Year fee-setting authority was introduced

2017

Last year fee-setting authority was amended

2025

Service standard

75 calendar days to complete Review 1

Performance result

100% (58/58 completed within service standard)

Application of *Low-Materiality Fees Regulations*

Not subject to *Service Fees Act*: Applications for Class IV licence

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
Applications for Class IV licence	29,405	1,610,428	0	April 1, 2026	30,713

Fee

Applications for Class IV licence amendment - changes in manufacturing

Fee-setting authority

- *Food and Drugs Act (FDA)*, 30.61(1)
- *Fees in Respect of Drugs and Medical Devices Order* (SOR/2019-124)

Year fee-setting authority was introduced

2017

Last year fee-setting authority was amended

2025

Service standard

75 calendar days to complete Review 1

Performance result

100% (38/38 completed within service standard)

Application of *Low-Materiality Fees Regulations*

Not subject to *Service Fees Act*: Applications for Class IV licence amendment - changes in manufacturing

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
Applications for Class IV licence amendment - changes in manufacturing	4,279	148,606	0	April 1, 2026	4,470

Fee

Applications for Class IV licence amendment - significant changes not related to manufacturing

Fee-setting authority

- *Food and Drugs Act (FDA)*, 30.61(1)
- *Fees in Respect of Drugs and Medical Devices Order* (SOR/2019-124)

Year fee-setting authority was introduced

2017

Last year fee-setting authority was amended

2025

Service standard

75 calendar days to complete Review 1

Performance result

100% (109/109 completed within service standard)

Application of *Low-Materiality Fees Regulations*

Not subject to *Service Fees Act*: Applications for Class IV licence amendment – significant changes not related to manufacturing

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
Applications for Class IV licence amendment - significant changes not related to manufacturing	15,558	1,815,719	0	April 1, 2026	16,251

Fee

Applications for Class II, III or IV licence or licence amendment - private label medical device

Fee-setting authority

- *Food and Drugs Act (FDA)*, 30.61(1)
- *Fees in Respect of Drugs and Medical Devices Order* (SOR/2019-124)

Year fee-setting authority was introduced

2017

Last year fee-setting authority was amended

2025

Service standard

15 calendar days to review

Performance result

99.3% (573/577 completed within service standard)

Application of *Low-Materiality Fees Regulations*

Not subject to *Service Fees Act*: Applications for Class II, III or IV licence or licence amendment - private label medical device

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
Applications for Class II, III or IV licence or licence amendment - private label medical device	171	74,502	128	April 1, 2026	179

Fees for Right to Sell a Licensed Class II, III or IV Medical Device

Health Canada monitors medical devices on the Canadian market through post-market surveillance and compliance and enforcement activities. There is an annual fee for the right to sell a Class II, III, IV medical device.

Fee

Medical Device Right to Sell

Fee-setting authority

- *Food and Drugs Act (FDA)*, 30.61(1)
- *Fees in Respect of Drugs and Medical Devices Order* (SOR/2019-124)

Year fee-setting authority was introduced

2017

Last year fee-setting authority was amended

2025

Service standard

20 days to update Medical Device Licence Listing database following receipt of a complete Annual Notification Package

Performance result

100% (34,833/34,833 were completed within service standard)

Application of *Low-Materiality Fees Regulations*

Not subject to *Service Fees Act*: Medical Device Right to Sell

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
Medical Device Right to Sell	440	13,946,715	0	April 1, 2026	460

Medical Device Establishment Licensing Fees

A Medical Device Establishment Licence (MDEL) is required for the activities of importing or selling medical devices for human use in Canada with exceptions¹. A fee is charged for the examination of an MDEL application, including all compliance and enforcement and supporting activities needed to ensure that the applicant/licence holder conforms to all regulatory requirements. The MDEL fee is a flat fee. The same fee is charged for an application for a new MDEL, an annual licence review of an MDEL, and the reinstatement of a suspended MDEL.

Fee

Medical Device Establishment Licensing Fees

Fee-setting authority

- *Food and Drugs Act (FDA)*, 30.61(1)
- *Fees in Respect of Drugs and Medical Devices Order* (SOR/2019-124)

Year fee-setting authority was introduced

2017

Last year fee-setting authority was amended

2025

Service standard

120 calendar days to issue/ renew licence

Performance result

100% (2,956/2,956) of licenses issued within 120 calendar days

Application of *Low-Materiality Fees Regulations*

Not subject to *Service Fees Act*: Application for new licence and annual review of licence

¹ As per the Medical Devices Regulations, an MDEL is not required for: a retailer, a health care facility, a manufacturer of Class II, III or IV medical devices who only sells either medical devices for which they hold a valid licence, or medical devices subject to Parts 2 and 3 of the Regulations, a manufacturer of a Class I medical device who imports or distributes solely through a licensed establishment, a person solely selling medical devices subject to Parts 2 and 3 of the Regulations, or a dispenser.

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
Application for new licence and annual review of licence	5,283	13,397,431	0	April 1, 2026	5,519

Fees to be Paid for the Examination of an Application in Respect of a Pest Control Product

No person shall manufacture, possess, handle, store, transport, import, distribute or use a pest control product that is not registered under the *Pest Control Products Act*, except as otherwise authorized under the Act or unless specifically exempted by the *Pest Control Products Regulations*. Fees for applications to register or to amend the registration of a pest control product are payable by component submitted. The fee payable is the sum of the fees for the submitted components in addition to the basic processing fee.

The following table reflects the total 2024-25 fee revenue by individual fee.

Fee	2024-25 total fee revenue (\$)
Processing	1,427,720
Applications not Mentioned in Schedules	242,146
Renewal	99,519
Schedule 1: Fees for Applications to Register, or to Amend the Registration of, a Pest Control Product Other Than a Semiochemical or Microbial Agent	
Product Chemistry – active ingredient	798,565
Product Chemistry – end-use product or manufacturing concentrate	396,346
Toxicology data accompanying an application to register a pest control product that contains a new active ingredient	142,566
Toxicology data accompanying an application to register a pest control product –or to amend a pest control product –that contains a registered active ingredient	42,737
Toxicology data-acute toxicity studies	169,555
Exposure data accompanying an application to register a pest control that consists of or that contains a new active ingredient	30,219
Exposure data accompanying an application to register a pest control product –or to amend the registration of a pest control product –that contains a registered active ingredient, when a new risk assessment is necessary	40,287
Exposure data-other	81,344
Metabolism data	97,806
Residue data	332,117
Environment fate data accompanying an application to register a pest control product that consists of or that contains a new active ingredient	73,710

Fee	2024-25 total fee revenue (\$)
Environmental fate data accompanying an application to register a pest control product ,or to amend the registration of a pest control product, that contains a registered active ingredient , when a new risk assessment is necessary	19,008
Environmental fate data-other	39,276
Environment toxicology data accompanying an application to register a pest control product that consists of or that contains a new active ingredient	92,067
Environmental toxicology data accompanying an application to register a pest control product ,or to amend the registration of a pest control product, that contains a registered active ingredient , when a new risk assessment is necessary	0
Environmental toxicology data-other	14,012
Value and effectiveness data for a pest control product	164,321
Identification of compensable data	510,418
Schedule 2: Fees for Applications in Respect of a Pest Control Product that is a Semiochemical or Microbial Agent	
Registration of a new active ingredient – food use	11,225
Registration of a new active ingredient – non-food use	3,056
Amendment of registration – new risk assessment necessary-environmental fate data, environmental toxicity data or exposure data	3,262
Amendment of registration – data required, label changes	9,098
Amendment of registration – data required, other	11,210
Amendment of registration – no data required	3,019
Registration of new active ingredient	0
Amendment of registration	616
Schedule 3: Fees for Other Applications in Respect of a Pest Control Product	
Research authorization – major crops, other than research authorizations set out in paragraphs (c) and (d)	220,386
Research authorization – minor use crops, other than research authorizations set out in paragraphs (c) and (d)	13,280
Research authorization – microbial agents, semiochemicals and any substance listed in subparagraph 1(d) (ii) of these regulations	14,000

Fee	2024-25 total fee revenue (\$)
Research authorization – greenhouse crops and non-agricultural uses	6,689
Research notifications	3,942
Registration of active ingredient to be used in pest control product manufactured only for export	0
Amendment to Registration of active ingredient to be used in pest control product manufactured only for export	2,612
Specification of maximum residue limit for a previously unexamined pest control product	141,293
Specification of maximum residue limit for an unregistered use of a previously examined pest control product	36,035

Fee

Category A Component Based - 655 days of Review (Conventional Chemicals and Import Maximum Residue Limits)

Fee-setting authority

- *Pest Control Products Act*, 63
- *Pest Control Products Fees and Charges Regulations* (SOR/2017-9)

Year fee-setting authority was introduced

2002

Last year fee-setting authority was amended

2024

Service standard

655 calendar days of Review

Performance result

78% (7/9 applications met the service standard)

Application of *Low-Materiality Fees Regulations*

Material (>\$151): All fees listed below

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
Product Chemistry - active ingredient	5,601	See the total fee revenue table	0	April 1, 2026	5,829
Product Chemistry - end-use product or manufacturing concentrate	3,120			April 1, 2026	3,247
Toxicology data accompanying an application to register a pest control product that contains a new active ingredient	87,082			April 1, 2026	90,601

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
Toxicology data accompanying an application to register a pest control product -or to amend a pest control product - that contains a registered active ingredient	18,186			April 1, 2026	18,921
Toxicology data - acute toxicity studies	3,397			April 1, 2026	3,535
Exposure data accompanying an application to register a pest control that consists of or that contains a new active ingredient	20,103			April 1, 2026	20,917
Exposure data accompanying an application to register a pest control product -or to amend the registration of a pest control product -that contains a registered active ingredient, when a new risk assessment is necessary	6,618			April 1, 2026	6,887
Metabolism data	33,250			April 1, 2026	34,594
Residue data	18,196			April 1, 2026	18,932
Environment fate data accompanying an application to register a pest control product that consists of or that contains a new active ingredient	49,035			April 1, 2026	51,017

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
Environmental fate data accompanying an application to register a pest control product, or to amend the registration of a pest control product, that contains a registered active ingredient, when a new risk assessment is necessary	27,154			April 1, 2026	28,252
Environment toxicology data accompanying an application to register a pest control product that consists of or that contains a new active ingredient	42,824			April 1, 2026	44,555
Environmental toxicology data accompanying an application to register a pest control product, or to amend the registration of a pest control product, that contains a registered active ingredient, when a new risk assessment is necessary	27,215			April 1, 2026	28,316
Value and effectiveness data for a pest control product	1,045			April 1, 2026	1,088
Specification of maximum residue limit for a previously unexamined pest control product	144,119			April 1, 2026	149,943
Specification of maximum residue limit for an unregistered use of a previously examined pest control product	18,196			April 1, 2026	18,932
Processing	1,306			April 1, 2026	1,360

Fee

Category A Component Based - 555 days (Reduced risk, other biopesticides, non-conventionals, non-straight-chain lepidopteran pheromone)

Fee-setting authority

- *Pest Control Products Act*, 63
- *Pest Control Products Fees and Charges Regulations* (SOR/2017-9)

Year fee-setting authority was introduced

2002

Last year fee-setting authority was amended

2024

Service standard

555 calendar days of Review

Performance result

77% (10/13 applications met the service standard)

Application of *Low-Materiality Fees Regulations*

Material (>\$151): All fees listed below

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
Product Chemistry - active ingredient	5,601	See the total fee revenue table	4,793	April 1, 2026	5,829
Product Chemistry - end-use product or manufacturing concentrate	3,120			April 1, 2026	3,247
Toxicology data accompanying an application to register a pest control product that contains a new active ingredient	87,082			April 1, 2026	90,601

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
Toxicology data accompanying an application to register a pest control product - or to amend a pest control product - that contains an registered active ingredient	18,186			April 1, 2026	18,921
Toxicology data - acute toxicity studies	3,397			April 1, 2026	3,535
Exposure data accompanying an application to register a pest control that consists of or that contains a new active ingredient	20,103			April 1, 2026	20,917
Exposure data accompanying an application to register a pest control product - or to amend the registration of a pest control product - that contains a registered active ingredient, when a new risk assessment is necessary	6,618			April 1, 2026	6,887
Metabolism data	33,250			April 1, 2026	34,594
Residue data	18,196			April 1, 2026	18,932
Environment fate data accompanying an application to register a pest control product that consists of or that contains a new active ingredient	49,035			April 1, 2026	51,017

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
Environmental fate data accompanying an application to register a pest control product, or to amend the registration of a pest control product, that contains a registered active ingredient, when a new risk assessment is necessary	27,154			April 1, 2026	28,252
Environment toxicology data accompanying an application to register a pest control product that consists of or that contains a new active ingredient	42,824			April 1, 2026	44,555
Environmental toxicology data accompanying an application to register a pest control product, or to amend the registration of a pest control product, that contains a registered active ingredient, when a new risk assessment is necessary	27,215			April 1, 2026	28,316
Value and effectiveness data for a pest control product	1,045			April 1, 2026	1,088
Registration of a new active ingredient - food use	8,315			April 1, 2026	8,652
Registration of a new active ingredient - non-food use	4,990			April 1, 2026	5,192

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
Amendment of registration - new risk assessment necessary - environmental fate data, environmental toxicity data or exposure data	3,328			April 1, 2026	3,463
Processing	1,306			April 1, 2026	1,360

Fee

Category A Component Based - 470 days of Review (Microbials including User Requested Minor Use Registration (URMUR), and URMUR for conventional chemical, reduced risk, other biopesticides, non-conventionals, non-straight-chain lepidopteran pheromone)

Fee-setting authority

- *Pest Control Products Act*, 63
- *Pest Control Products Fees and Charges Regulations* (SOR/2017-9)

Year fee-setting authority was introduced

2002

Last year fee-setting authority was amended

2024

Service standard

470 calendar days of Review

Performance result

75% (6/8 applications met the service standard)

Application of *Low-Materiality Fees Regulations*

Material (>\$151): All fees listed below

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
Product Chemistry - active ingredient	5,601	See the total fee revenue table	876	April 1, 2026	5,829
Product Chemistry - end-use product or manufacturing concentrate	3,120			April 1, 2026	3,247

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
Toxicology data accompanying an application to register a pest control product that contains a new active ingredient	87,082			April 1, 2026	90,601
Toxicology data accompanying an application to register a pest control product - or to amend a pest control product -that contains an registered active ingredient	18,186			April 1, 2026	18,921
Toxicology data - acute toxicity studies	3,397			April 1, 2026	3,535
Exposure data accompanying an application to register a pest control that consists of or that contains a new active ingredient	20,103			April 1, 2026	20,917
Exposure data accompanying an application to register a pest control product - or to amend the registration of a pest control product - that contains a registered active ingredient, when a new risk assessment is necessary	6,618			April 1, 2026	6,887
Metabolism data	33,250			April 1, 2026	34,594
Residue data	18,196			April 1, 2026	18,932

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
Environment fate data accompanying an application to register a pest control product that consists of or that contains a new active ingredient	49,035			April 1, 2026	51,017
Environmental fate data accompanying an application to register a pest control product, or to amend the registration of a pest control product, that contains a registered active ingredient, when a new risk assessment is necessary	27,154			April 1, 2026	28,252
Environment toxicology data accompanying an application to register a pest control product that consists of or that contains a new active ingredient	42,824			April 1, 2026	44,555
Environmental toxicology data accompanying an application to register a pest control product, or to amend the registration of a pest control product, that contains a registered active ingredient, when a new risk assessment is necessary	27,215			April 1, 2026	28,316
Value and effectiveness data for a pest control product	1,045			April 1, 2026	1,088
Registration of a new active ingredient - food use	8,315			April 1, 2026	8,652

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
Registration of a new active ingredient - non-food use	4,990			April 1, 2026	5,192
Amendment of registration - new risk assessment necessary - environmental fate data, environmental toxicity data or exposure data	3,328			April 1, 2026	3,463
Processing	1,306			April 1, 2026	1,360

Fee

Category A Component Based - 285 days of Review (Straight-chain lepidopteran pheromones, including User Requested Minor Use Registration)

Fee-setting authority

- *Pest Control Products Act*, 63
- *Pest Control Products Fees and Charges Regulations* (SOR/2017-9)

Year fee-setting authority was introduced

2002

Last year fee-setting authority was amended

2024

Service standard

285 calendar days of Review

Performance result

N/A (0 applications completed in 2024-25)

Application of *Low-Materiality Fees Regulations*

Material (>\$151): All fees listed below

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
Registration of new active ingredient	669	See the total fee revenue table	0	April 1, 2026	697
Amendment of registration	337			April 1, 2026	351

Fee

Category A Component Based - Submissions with atypical timelines and joint reviews

Fee-setting authority

- *Pest Control Products Act*, 63
- *Pest Control Products Fees and Charges Regulations* (SOR/2017-9)

Year fee-setting authority was introduced

2002

Last year fee-setting authority was amended

2024

Service standard

Variable as per Management of Submission Policy Appendix I, [table 1](#)

Performance result

40% (2/5 applications met the service standard)

Application of *Low-Materiality Fees Regulations*

Material (>\$151): All fees listed below

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
Product Chemistry - active ingredient	5,601	See the total fee revenue table	0	April 1, 2026	5,829
Product Chemistry - end-use product or manufacturing concentrate	3,120			April 1, 2026	3,247
Toxicology data accompanying an application to register a pest control product that contains a new active ingredient	87,082			April 1, 2026	90,601

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
Toxicology data accompanying an application to register a pest control product - or to amend a pest control product - that contains an registered active ingredient	18,186			April 1, 2026	18,921
Toxicology data - acute toxicity studies	3,397			April 1, 2026	3,535
Exposure data accompanying an application to register a pest control that consists of or that contains a new active ingredient	20,103			April 1, 2026	20,917
Exposure data accompanying an application to register a pest control product - or to amend the registration of a pest control product - that contains a registered active ingredient, when a new risk assessment is necessary	6,618			April 1, 2026	6,887
Metabolism data	33,250			April 1, 2026	34,594
Residue data	18,196			April 1, 2026	18,932
Environment fate data accompanying an application to register a pest control product that consists of or that contains a new active ingredient	49,035			April 1, 2026	51,017

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
Environmental fate data accompanying an application to register a pest control product, or to amend the registration of a pest control product, that contains a registered active ingredient, when a new risk assessment is necessary	27,154			April 1, 2026	28,252
Environment toxicology data accompanying an application to register a pest control product that consists of or that contains a new active ingredient	42,824			April 1, 2026	44,555
Environmental toxicology data accompanying an application to register a pest control product, or to amend the registration of a pest control product, that contains a registered active ingredient, when a new risk assessment is necessary	27,215			April 1, 2026	28,316
Value and effectiveness data for a pest control product	1,045			April 1, 2026	1,088
Registration of a new active ingredient - food use	8,315			April 1, 2026	8,652
Registration of a new active ingredient - non-food use	4,990			April 1, 2026	5,192

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
Amendment of registration - new risk assessment necessary - environmental fate data, environmental toxicity data or exposure data	3,328			April 1, 2026	3,463
Registration of new active ingredient	669			April 1, 2026	697
Amendment of registration	337			April 1, 2026	351
Specification of maximum residue limit for a previously unexamined pest control product	144,119			April 1, 2026	149,943
Specification of maximum residue limit for an unregistered use of a previously examined pest control product	18,196			April 1, 2026	18,932
Processing	1,306			April 1, 2026	1,360

Fee

Category B Component Based - 425 days of Review (Conventional Chemicals including emergency use and New Import Maximum Residue Limits for previously assessed active ingredient)

Fee-setting authority

- *Pest Control Products Act*, 63
- *Pest Control Products Fees and Charges Regulations* (SOR/2017-9)

Year fee-setting authority was introduced

2002

Last year fee-setting authority was amended

2024

Service standard

425 calendar days of Review

Performance result

91% (144/159 applications met the service standard)

Application of *Low-Materiality Fees Regulations*

Material (>\$151): All fees listed below

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
Product Chemistry - active ingredient	5,601	See the total fee revenue table	11,582	April 1, 2026	5,829
Product Chemistry - end-use product or manufacturing concentrate	3,120			April 1, 2026	3,247

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
Toxicology data accompanying an application to register a pest control product - or to amend a pest control product - that contains an registered active ingredient	18,186			April 1, 2026	18,921
Toxicology data - acute toxicity studies	3,397			April 1, 2026	3,535
Exposure data - other	5,993			April 1, 2026	6,236
Metabolism data	33,250			April 1, 2026	34,594
Residue data	18,196			April 1, 2026	18,932
Environmental fate data - other	13,266			April 1, 2026	13,803
Environmental toxicology data - other	2,836			April 1, 2026	2,951
Value and effectiveness data for a pest control product	1,045			April 1, 2026	1,088
Specification of maximum residue limit for an unregistered use of a previously examined pest control product	18,196			April 1, 2026	18,932
Processing	1,306			April 1, 2026	1,360

Fee

Category B Component Based - 360 days of Review (Reduced risk, other biopesticides, non-conventionals, non-straight chain lepidopteran pheromone including emergency use)

Fee-setting authority

- *Pest Control Products Act*, 63
- *Pest Control Products Fees and Charges Regulations* (SOR/2017-9)

Year fee-setting authority was introduced

2002

Last year fee-setting authority was amended

2024

Service standard

360 calendar days of Review

Performance result

75% (21/28 applications met the service standard)

Application of *Low-Materiality Fees Regulations*

Material (>\$151): All fees listed below

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
Product Chemistry - active ingredient	5,601	See the total fee revenue table	1,367	April 1, 2026	5,829
Product Chemistry - end-use product or manufacturing concentrate	3,120			April 1, 2026	3,247
Toxicology data accompanying an application to register a pest control product - or to amend a pest control product - that contains an	18,186			April 1, 2026	18,921

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
registered active ingredient					
Toxicology data - acute toxicity studies	3,397			April 1, 2026	3,535
Exposure data - other	5,993			April 1, 2026	6,236
Metabolism data	33,250			April 1, 2026	34,594
Residue data	18,196			April 1, 2026	18,932
Environmental fate data - other	13,266			April 1, 2026	13,803
Environmental toxicology data - other	2,836			April 1, 2026	2,951
Value and effectiveness data for a pest control product	1,045			April 1, 2026	1,088
Amendment of registration - data required, label changes	1,665			April 1, 2026	1,733
Amendment of registration - data required, other	1,335			April 1, 2026	1,390
Processing	1,306			April 1, 2026	1,360

Fee

Category B Component Based - 240 days of Review (Microbials and straight chain lepidopteran pheromones including emergency use)

Fee-setting authority

- *Pest Control Products Act*, 63
- *Pest Control Products Fees and Charges Regulations* (SOR/2017-9)

Year fee-setting authority was introduced

2002

Last year fee-setting authority was amended

2024

Service standard

240 calendar days of Review

Performance result

82% (14/17 applications met the service standard)

Application of *Low-Materiality Fees Regulations*

Material (>\$151): All fees listed below

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
Amendment of registration - data required, label changes	1,665	See the total fee revenue table	1,136	April 1, 2026	1,733
Amendment of registration - data required, other	1,335			April 1, 2026	1,390
Amendment of registration	337			April 1, 2026	351

Fee

Category B Component Based - 158 days of Review (Streamlined; application rate changes, tank mixes, new pests or changes to level of control)

Fee-setting authority

- *Pest Control Products Act*, 63
- *Pest Control Products Fees and Charges Regulations* (SOR/2017-9)

Year fee-setting authority was introduced

2002

Last year fee-setting authority was amended

2024

Service standard

158 calendar days of Review

Performance result

100% (117/117 applications met the service standard)

Application of *Low-Materiality Fees Regulations*

Material (>\$151): All fees listed below

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
Value and effectiveness data for a pest control product	1,045	See the total fee revenue table	0	April 1, 2026	1,088
Amendment of registration - data required, label changes	1,665			April 1, 2026	1,733
Amendment of registration - no data required, other	337			April 1, 2026	351
Processing	1,306			April 1, 2026	1,360

Fee

Category B Component Based - Submissions with atypical timelines and joint reviews

Fee-setting authority

- *Pest Control Products Act*, 63
- *Pest Control Products Fees and Charges Regulations* (SOR/2017-9)

Year fee-setting authority was introduced

2002

Last year fee-setting authority was amended

2024

Service standard

Variable as per Management of Submission Policy Appendix I, [table 2](#)

Performance result

58% (7/12 applications met the service standard)

Application of *Low-Materiality Fees Regulations*

Material (>\$151): All fees listed below

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
Product Chemistry - active ingredient	5,601	See the total fee revenue table	0	April 1, 2026	5,829
Product Chemistry - end-use product or manufacturing concentrate	3,120			April 1, 2026	3,247
Toxicology data accompanying an application to register a pest control product - or to amend a pest control product - that contains an registered active ingredient	18,186			April 1, 2026	18,921

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
Toxicology data-acute toxicity studies	3,397			April 1, 2026	3,535
Exposure data-other	5,993			April 1, 2026	6,236
Metabolism data	33,250			April 1, 2026	34,594
Residue data	18,196			April 1, 2026	18,932
Environmental fate data - other	13,266			April 1, 2026	13,803
Environmental toxicology data - other	2,836			April 1, 2026	2,951
Value and effectiveness data for a pest control product	1,045			April 1, 2026	1,088
Amendment of registration - data required, label changes	1,665			April 1, 2026	1,733
Amendment of registration - data required, other	1,335			April 1, 2026	1,390
Amendment of registration - no data required	337			April 1, 2026	351
Amendment of registration	337			April 1, 2026	351
Specification of maximum residue limit for an unregistered use of a previously examined pest control product	18,196			April 1, 2026	18,932
Processing	1,306			April 1, 2026	1,360

Fee

Category C Component Based - 240 days of Review (New/Changes to Product Labels, Addition of Approved Minor Use, Similar Product)

Fee-setting authority

- *Pest Control Products Act*, 63
- *Pest Control Products Fees and Charges Regulations* (SOR/2017-9)

Year fee-setting authority was introduced

2002

Last year fee-setting authority was amended

2024

Service standard

240 calendar days of Review

Performance result

61% (449/734 applications met the service standard)

Application of *Low-Materiality Fees Regulations*

Material (>\$151): All fees listed below

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
Amendment of registration - no data required	337	See the total fee revenue table	58,979	April 1, 2026	351
Amendment of registration	337			April 1, 2026	351
Processing	1,306			April 1, 2026	1,360

Fee

Category C Component Based - 180 days of Review (New/Changes to TGAI, ISP, MA or EP Product Chemistry, Administrative Changes, Administrative Re-instatement)

Fee-setting authority

- *Pest Control Products Act*, 63
- *Pest Control Products Fees and Charges Regulations* (SOR/2017-9)

Year fee-setting authority was introduced

2002

Last year fee-setting authority was amended

2024

Service standard

180 calendar days of Review

Performance result

85% (63/74 applications met the service standard)

Application of *Low-Materiality Fees Regulations*

Material (>\$151): All fees listed below

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
Amendment of registration - no data required	337	See the total fee revenue table	1,268	April 1, 2026	351
Amendment of registration	337			April 1, 2026	351
Processing	1,306			April 1, 2026	1,360

Fee

Category C Component Based - Submissions with atypical timelines and joint reviews

Fee-setting authority

- *Pest Control Products Act*, 63
- *Pest Control Products Fees and Charges Regulations* (SOR/2017-9)

Year fee-setting authority was introduced

2002

Last year fee-setting authority was amended

2024

Service standard

Variable as per Management of Submission Policy Appendix I, [table 3](#)

Performance result

N/A (0 applications completed in 2024-25)

Application of *Low-Materiality Fees Regulations*

Material (>\$151): All fees listed below

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
Amendment of registration - no data required	337	See the total fee revenue table	0	April 1, 2026	351
Amendment of registration	337			April 1, 2026	351
Processing	1,306			April 1, 2026	1,360

Fee

Category D Component Based - 285 days of Review (Registration Renewal)

Fee-setting authority

- *Pest Control Products Act*, 63
- *Pest Control Products Fees and Charges Regulations* (SOR/2017-9)

Year fee-setting authority was introduced

2002

Last year fee-setting authority was amended

2024

Service standard

285 calendar days of Review (The number of days from the issuance of the renewal notice to March 15 of the following year)

Performance result

100% (1,053/1,053 applications met the service standard)

Application of *Low-Materiality Fees Regulations*

Low-materiality (\$51-\$151) : Registration Renewal

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
Registration Renewal	94	See the total fee revenue table	0	April 1, 2026	98

Fee

Category D Component Based – 46 Days of Review (Registration/Amendment to Registration of active ingredient to be used in pest control product manufactured only for export)

Fee-setting authority

- *Pest Control Products Act*, 63
- *Pest Control Products Fees and Charges Regulations* (SOR/2017-9)

Year fee-setting authority was introduced

2002

Last year fee-setting authority was amended

2024

Service standard

46 calendar days of Review

Performance result

N/A (0 applications completed in 2024-25)

Application of *Low-Materiality Fees Regulations*

Material (>\$151): All fees listed below

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
Registration of active ingredient to be used in pest control product manufactured only for export	8,994	See the total fee revenue table	0	April 1, 2026	9,358
Amendment to Registration of active ingredient to be used in pest control product manufactured only for export	1,306			April 1, 2026	1,360

Fee

Category D Component Based - 42 days of Review (Master Copies)

Fee-setting authority

- *Pest Control Products Act*, 63
- *Pest Control Products Fees and Charges Regulations* (SOR/2017-9)

Year fee-setting authority was introduced

2002

Last year fee-setting authority was amended

2024

Service standard

42 calendar days of Review

Performance result

97% (111/114 applications met the service standard)

Application of *Low-Materiality Fees Regulations*

Material (>\$151): All fees listed below

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
Processing	1,306	See the total fee revenue table	223	April 1, 2026	1,360

Fee

Category D Component Based - 10 days of Review (Private Labels)

Fee-setting authority

- *Pest Control Products Act*, 63
- *Pest Control Products Fees and Charges Regulations* (SOR/2017-9)

Year fee-setting authority was introduced

2002

Last year fee-setting authority was amended

2024

Service standard

10 calendar days of Review

Performance result

100% (4/4 applications met the service standard)

Application of *Low-Materiality Fees Regulations*

Material (>\$151): All fees listed below

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
Processing	1,306	See the total fee revenue table	0	April 1, 2026	1,360

Fee

Category E Component Based - 159 days of Review (Research Authorizations for New Technical Grade Active Ingredients)

Fee-setting authority

- *Pest Control Products Act*, 63
- *Pest Control Products Fees and Charges Regulations* (SOR/2017-9)

Year fee-setting authority was introduced

2002

Last year fee-setting authority was amended

2024

Service standard

159 calendar days of Review

Performance result

50% (9/18 applications met the service standard)

Application of *Low-Materiality Fees Regulations*

Material (>\$151): All fees listed below

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
Research authorization - major crops, other than research authorizations set out in paragraphs (c) and (d)	5,838	See the total fee revenue table	6,844	April 1, 2026	6,075
Research authorization - minor use crops, other than research authorizations set out in paragraphs (c) and (d)	5,838			April 1, 2026	6,075
Research authorization - microbial agents, semiochemicals and any substance listed in	1,401			April 1, 2026	1,459

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
subparagraph 1(d) (ii) of these regulations					
Research authorization - greenhouse crops and non-agricultural uses	1,401			April 1, 2026	1,459

Fee

Category E Component Based - 69 days of Review (Research Authorizations for New Uses of Registered Active Ingredients)

Fee-setting authority

- *Pest Control Products Act*, 63
- *Pest Control Products Fees and Charges Regulations* (SOR/2017-9)

Year fee-setting authority was introduced

2002

Last year fee-setting authority was amended

2024

Service standard

69 calendar days of Review

Performance result

81% (35/43 applications met the service standard)

Application of *Low-Materiality Fees Regulations*

Material (>\$151): All fees listed below

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
Research authorization - major crops, other than research authorizations set out in paragraphs (c) and (d)	5,838	See the total fee revenue table	7,645	April 1, 2026	6,075
Research authorization - minor use crops, other than research authorizations set out in paragraphs (c) and (d)	5,838			April 1, 2026	6,075
Research authorization - microbial agents, semiochemicals and any substance listed in	1,401			April 1, 2026	1,459

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
subparagraph 1(d) (ii) of these regulations					
Research authorization - greenhouse crops and non-agricultural uses	1,401			April 1, 2026	1,459

Fee

Category E Component Based - 30 days of Review (Research Notification for Research Carried out in Canada)

Fee-setting authority

- *Pest Control Products Act*, 63
- *Pest Control Products Fees and Charges Regulations* (SOR/2017-9)

Year fee-setting authority was introduced

2002

Last year fee-setting authority was amended

2024

Service standard

30 calendar days of Review

Performance result

94% (16/17 applications met the service standard)

Application of *Low-Materiality Fees Regulations*

Material (>\$151): All fees listed below

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
Research notifications	288	See the total fee revenue table	72	April 1, 2026	300

Fee

Category F Component Based - 45 days of Review (Registration and amendments to registered pest control products via notification)

Fee-setting authority

- *Pest Control Products Act*, 63
- *Pest Control Products Fees and Charges Regulations* (SOR/2017-9)

Year fee-setting authority was introduced

2002

Last year fee-setting authority was amended

2024

Service standard

45 calendar days of Review

Performance result

91% (772/846 applications met the service standard)

Application of *Low-Materiality Fees Regulations*

Material (>\$151): All fees listed below

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
Applications not mentioned in schedules	288	See the total fee revenue table	2,363	April 1, 2026	300

Fee

Category L Component Based - 425 days of Review (Equivalency and data compensation assessment of end-use product and manufacturing concentrate with partial data package - conventional chemical)

Fee-setting authority

- *Pest Control Products Act*, 63
- *Pest Control Products Fees and Charges Regulations* (SOR/2017-9)

Year fee-setting authority was introduced

2002

Last year fee-setting authority was amended

2024

Service standard

425 calendar days of Review

Performance result

92% (79/86 applications met the service standard)

Application of *Low-Materiality Fees Regulations*

Material (>\$151): All fees listed below

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
Product Chemistry - active ingredient	5,601	See the total fee revenue table	4,461	April 1, 2026	5,829
Product Chemistry - end-use product or manufacturing concentrate	3,120			April 1, 2026	3,247
Toxicology data accompanying an application to register a pest control product -or to amend a pest control product -that contains an	18,186			April 1, 2026	18,921

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
registered active ingredient					
Toxicology data-acute toxicity studies	3,397			April 1, 2026	3,535
Exposure data - other	5,993			April 1, 2026	6,236
Metabolism data	33,250			April 1, 2026	34,594
Residue data	18,196			April 1, 2026	18,932
Environmental fate data - other	13,266			April 1, 2026	13,803
Environmental toxicology data - other	2,836			April 1, 2026	2,951
Value and effectiveness data for a pest control product	1,045			April 1, 2026	1,088
Identification of compensable data	2,487			April 1, 2026	2,588
Processing	1,306			April 1, 2026	1,360

Fee

Category L Component Based - 365 days of Review (Equivalency and data compensation assessment of active ingredient, end-use product and manufacturing concentrate with no data)

Fee-setting authority

- *Pest Control Products Act*, 63
- *Pest Control Products Fees and Charges Regulations* (SOR/2017-9)

Year fee-setting authority was introduced

2002

Last year fee-setting authority was amended

2024

Service standard

365 calendar days of Review

Performance result

87% (97/111 applications met the service standard)

Application of *Low-Materiality Fees Regulations*

Material (>\$151): All fees listed below

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
Product Chemistry - active ingredient	5,601	See the total fee revenue table	10,304	April 1, 2026	5,829
Product Chemistry - end-use product or manufacturing concentrate	3,120			April 1, 2026	3,247
Identification of compensable data	2,487			April 1, 2026	2,588
Processing	1,306			April 1, 2026	1,360

Fee

Category L Component Based – 360 days of Review (Equivalency and data compensation assessment of end-use product and manufacturing concentrate with partial data package - reduced risk, other biopesticides, non-conventionals, non-straight chain lepidopteran pheromone)

Fee-setting authority

- *Pest Control Products Act*, 63
- *Pest Control Products Fees and Charges Regulations* (SOR/2017-9)

Year fee-setting authority was introduced

2002

Last year fee-setting authority was amended

2024

Service standard

360 calendar days of Review

Performance result

100% (2/2 applications met the service standard)

Application of *Low-Materiality Fees Regulations*

Material (>\$151): All fees listed below

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
Product Chemistry - active ingredient	5,601	See the total fee revenue table	0	April 1, 2026	5,829
Product Chemistry - end-use product or manufacturing concentrate	3,120			April 1, 2026	3,247
Toxicology data accompanying an application to register a pest control product -or to amend a pest control product -that contains an	18,186			April 1, 2026	18,921

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
registered active ingredient					
Toxicology data-acute toxicity studies	3,397			April 1, 2026	3,535
Exposure data - other	5,993			April 1, 2026	6,236
Metabolism data	33,250			April 1, 2026	34,594
Residue data	18,196			April 1, 2026	18,932
Environmental fate data - other	13,266			April 1, 2026	13,803
Environmental toxicology data - other	2,836			April 1, 2026	2,951
Value and effectiveness data for a pest control product	1,045			April 1, 2026	1,088
Identification of compensable data	2,487			April 1, 2026	2,588
Amendment of registration - data required, label changes	1,665			April 1, 2026	1,733
Amendment of registration - data required, other	1,335			April 1, 2026	1,390
Processing	1,306			April 1, 2026	1,360

Fee

Category L Component Based 240 days of Review (Equivalency and data compensation assessment of end-use product and manufacturing concentrate with partial data package - microbials and straight chain lepidopteran pheromone)

Fee-setting authority

- *Pest Control Products Act*, 63
- *Pest Control Products Fees and Charges Regulations* (SOR/2017-9)

Year fee-setting authority was introduced

2002

Last year fee-setting authority was amended

2024

Service standard

240 calendar days of Review

Performance result

N/A (0 applications completed in 2024-25)

Application of *Low-Materiality Fees Regulations*

Material (>\$151): All fees listed below

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
Identification of compensable data	2,487	See the total fee revenue table	0	April 1, 2026	2,588
Amendment of registration - data required, label changes	1,665			April 1, 2026	1,733
Amendment of registration - data required, other	1,335			April 1, 2026	1,390
Amendment of registration	337			April 1, 2026	351
Processing	1,306			April 1, 2026	1,360

Fee

Category L Component Based – Applications with atypical timelines (Tailgaters, renegotiated timelines, synchronized timelines, coordination with Re-Evaluation)

Fee-setting authority

- *Pest Control Products Act*, 63
- *Pest Control Products Fees and Charges Regulations* (SOR/2017-9)

Year fee-setting authority was introduced

2002

Last year fee-setting authority was amended

2024

Service standard

Variable as per Management of Submission Policy Appendix I, [table 7](#)

Performance result

100% (3/3 applications met the service standard)

Application of *Low-Materiality Fees Regulations*

Material (>\$151): All fees listed below

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
Product Chemistry - active ingredient	5,601	See the total fee revenue table	0	April 1, 2026	5,829
Product Chemistry - end-use product or manufacturing concentrate	3,120			April 1, 2026	3,247
Toxicology data accompanying an application to register a pest control product -or to amend a pest control product -that contains an	18,186			April 1, 2026	18,921

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
registered active ingredient					
Toxicology data-acute toxicity studies	3,397			April 1, 2026	3,535
Exposure data - other	5,993			April 1, 2026	6,236
Metabolism data	33,250			April 1, 2026	34,594
Residue data	18,196			April 1, 2026	18,932
Environmental fate data - other	13,266			April 1, 2026	13,803
Environmental toxicology data - other	2,836			April 1, 2026	2,951
Value and effectiveness data for a pest control product	1,045			April 1, 2026	1,088
Identification of compensable data	2,487			April 1, 2026	2,588
Amendment of registration - data required, label changes	1,665			April 1, 2026	1,733
Amendment of registration - data required, other	1,335			April 1, 2026	1,390
Amendment of registration	337			April 1, 2026	351
Processing	1,306			April 1, 2026	1,360

Annual Charge (for a registered Pest Control Product)

A registrant must pay each year, in respect of every pest control product that is registered in their name on April 1 of the year, an annual charge. All registered products including technical grade active ingredients (TGAI), import for manufacturing and export program (IMEPs), private label products and master copies must pay the annual charge.

Fee

Annual Charge

Fee-setting authority

- *Pest Control Products Act*, 63
- *Pest Control Products Fees and Charges Regulations* (SOR/2017-9)

Year fee-setting authority was introduced

2002

Last year fee-setting authority was amended

2024

Service standard

Invoice is issued by April 30th 2024 or within 30 days of submitting a completed form (if after April 30th)

Performance result

100% of invoices were issued on time

Application of *Low-Materiality Fees Regulations*

Material (>\$151): All fees listed below

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
Annual Charge	The lesser of \$4,317.93 and 4% of the actual gross revenue during the registrant's preceding	10,284,768	0	April 1, 2026	The lesser of \$4,509.90 and 4% of the actual gross revenue during the registrant's preceding

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
	fiscal year, but not less than \$119.93				fiscal year, but not less than \$125.26

Fees Charged for Filing a Claim for Exemption under the *Hazardous Materials Information Review Act*

When a supplier or employer wants to be exempt from having to disclose confidential business information (CBI), such as the chemical identity of one or more trade-secret hazardous ingredients, they must file a claim for exemption with Health Canada.

Fee

- Original Claims
- Refiled Claims

Note: A 50% fee reduction is available for small businesses that meet certain criteria

Fee-setting authority:

- *Hazardous Materials Information Review Act*, 48(2)
- *Hazardous Materials Information Review Regulations* (SOR/88-456)

Year fee-setting authority was introduced

1988

Last year fee-setting authority was amended

2020

Service standard

Up to 15 claims – 10 business days

Between 16 and 25 claims – 15 business days

26+ claims – 20 business days

Performance result

99% of claims (original and refiled) were registered within the service standard

Application of *Low-Materiality Fees Regulations*

Material (>\$151): All fees listed below

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
Original Claim (up to 15)	2,158.97	400,530	1,057	April 1, 2026	2,254.95

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
Original Claim (between 16-25)	479.78			April 1, 2026	501.11
Original Claim (26+)	239.88			April 1, 2026	250.55
Refiled Claims (up to 15)	1,727.18	27,562	0	April 1, 2026	1,803.96
Refiled Claims (between 16-25)	383.82			April 1, 2026	400.88
Refiled Claims (26+)	191.91			April 1, 2026	200.44

Cannabis Fees

Fees are charged for the following transactional activities: application screening, security clearances, and import/export permits. In addition, an Annual Regulatory Fee is charged which covers costs associated with a range of regulatory activities including regulatory inspections, compliance and enforcement, program management and oversight. These activities are carried out by Health Canada, the Canada Border Services Agency, the Public Health Agency of Canada and Public Safety Canada to support the objectives of the *Cannabis Act* with respect to the legislation and regulations of cannabis.

Fee

Licence Application Screening Fees

Fee-setting authority

- [Cannabis Act](#), 142(1)
- [Cannabis Fees Order](#) (SOR/2018-198)

Year fee-setting authority was introduced

2018

Last year fee-setting authority was amended

2024

Service standard

Health Canada is committed to a non-binding administrative service standard of 30 business days for the screening of new licence applications. The standard excludes time spent awaiting additional information from applicants.

Performance result

The non-binding administrative standard was met 93% of the time.

Application of *Low-Materiality Fees Regulations*

Not subject to *Service Fees Act*: All fees listed below

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
Licence Application Screening Fee - Licence for micro-cultivation	1,969	231,953	This fee was not	April 1, 2026	2,058

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
Licence Application Screening Fee - Licence for standard cultivation	3,933		subject to remissions	April 1, 2026	4,109
Licence Application Screening Fee - Licence for a nursery	1,969			April 1, 2026	2,058
Licence Application Screening Fee - Licence for micro-processing	1,969			April 1, 2026	2,058
Licence Application Screening Fee - Licence for standard processing	3,933			April 1, 2026	4,109
Licence Application Screening Fee - Licence for sale for medical purposes	3,933			April 1, 2026	4,109

Fee

Application for a Security Clearance

Fee-setting authority

- *Cannabis Act*, 142(1)
- *Cannabis Fees Order* (SOR/2018-198)

Year fee-setting authority was introduced

2018

Last year fee-setting authority was amended

2024

Service standard

No administrative service standard for this fee as outlined during the 2018 consultation on the Proposed Approach to Cost Recovery for the Regulation of Cannabis and the subsequent Regulatory Impact Analysis Statement for the *Cannabis Fees Order*.

Performance result

Not applicable

Application of *Low-Materiality Fees Regulations*

Not subject to *Service Fees Act*: Application for a Security Clearance

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
Application for a Security Clearance	1,987	2,037,876	This fee was not subject to remissions	April 1, 2026	2,076

Fee

Application for Import or Export Permit

Fee-setting authority

- *Cannabis Act*, 142(1)
- *Cannabis Fees Order* (SOR/2018-198)

Year fee-setting authority was introduced

2018

Last year fee-setting authority was amended

2024

Service standard

Health Canada commits to a non-binding administrative service standard of 30 business days from the date that payment is received for the application to the issuance or rejection of the permit. The standard excludes time spent awaiting additional information from applicants.

Performance result

The non-binding administrative standard was met 99.9% of the time

Application of *Low-Materiality Fees Regulations*

Not subject to *Service Fees Act*: Application for Import or Export Permit

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
Application for Import or Export Permit	734	2,564,639	This fee was not subject to remissions	April 1, 2026	767

Fee

Annual Regulatory Fee

Fee-setting authority

- [Cannabis Act](#), 142(1)
- [Cannabis Fees Order](#) (SOR/2018-198)

Year fee-setting authority was introduced

2018

Last year fee-setting authority was amended

2024

Service standard

No administrative service standard for this fee as outlined during the 2018 consultation on the Proposed Approach to Cost Recovery for the Regulation of Cannabis and the subsequent Regulatory Impact Analysis Statement for the *Cannabis Fees Order*.

Performance result

Not applicable

Application of *Low-Materiality Fees Regulations*

Not subject to *Service Fees Act*: All fees listed below

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
Annual fee - Licence for micro-cultivation	as per Cannabis Fees Order	56,747,903	This fee was not subject to remissions	Exempt	as per Cannabis Fees Order
Annual fee - Licence for standard cultivation					
Annual fee - Licence for a nursery					
Annual fee - Licence for micro-processing					
Annual fee - Licence for standard processing					
Annual fee - Licence for sale for medical purposes					

National Dosimetry Products and Services Fees

National Dosimetry Services (NDS) provides radiation monitoring services to Canadians who are exposed to radiation in their work environment. NDS provides commercial dosimetry services to over 100,000 individuals working in over 12,500 organizations and operates on a cost-recovery basis. There are a number of components to NDS that are billed on a regular basis. These fees include the annual support fee, the shipping and handling fee and the processing fee. Other fees are billed depending on whether additional services are requested or if a dosimeter is overdue, late, lost or damaged.

Fee

National Dosimetry Products and Services Fees

Fee-setting authority

- Minister's Authority
- Fees notice published in [Canada Gazette](#)

Year fee-setting authority was introduced

2004

Last year fee-setting authority was amended

2024

Service standard

Provide timely, responsive and reliable dosimetry services:

1. Exposures reported to the National Dose Registry within 45 calendar days of receipt - Canadian Nuclear Safety Commission (CNSC) regulatory standard;
2. Dosimeters shipped 10-15 business days prior to exchange date with clients;
3. Dose results for whole body and extremity services reported to clients within internal service standards of 10- 20 business days, depending on the dosimetry service;
4. Client account information updated within two business days;
5. Client voice mails responded to within two business days; and
6. Client emails responded to within two business days.

Performance result

1. 100% compliance within the 45 calendar day regulatory (CNSC) standard;
2. Shipped 98% of dosimeters within 10-15 business days prior to exchange date;
3. 97% reported within internal standard of 10-20 business days, depending on the dosimetry service.
4. 96% completed within two business days;

5. 95% addressed within two business days; and
6. 95% addressed within two business days.

Application of *Low-Materiality Fees Regulations*

Not subject to section 17 of the *Service Fees Act*

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
Annual support	98.75	Not available	This fee was not subject to remissions	April 1, 2026	103.10
Annual support - multi-group discount (5+ groups)	65.00	Not available			67.90
Shipping and handling (per shipment)	14.50	Not available			14.50
Processing fees (per dosimeter)	6.00 to 17.50	Not available			6.30 to 18.30
Ad hoc dosimeter request - add-on (per shipment)	75.00	Not available			75.00
Priority processing request (per request)	110.00	Not available			110.00
Pregnancy service (semi-monthly)	375.00	Not available			375.00
Electronic personal dosimeter rental (per 9 months)	322.50	Not available			322.50
Electronic personal dosimeter rental with beta module (per 9 months)	375.00	Not available			375.00
Specialized consultation (per hour)	125.00	Not available			125.00
Customized reporting (per hour)	70.00	Not available			70.00
NDR dose modifications (per hour)	75.00	Not available			75.00

Fee	2024-25 fee amount (\$)	2024-25 total fee revenue (\$)	2024-25 total remissions issued for the fee (\$)	Fee adjustment date in 2026-27	2026-27 fee amount (\$)
Reprinting reports (per report)	25.00	Not available			25.00
Overdue dosimeter (three months after wearing period ends)	48.50	Not available			48.50
Late dosimeter (six months after wearing period ends)	48.50	Not available			48.50
Lost/damaged dosimeter	80.00	Not available			80.00
Damaged electronic personal dosimeter	430.00	Not available			430.00
Credit upon returning overdue dosimeter	24.00	Not available			24.00
Credit upon returning late or lost dosimeter	40.00	Not available			40.00